Editorial Board of Discovery Medicine



Editor-in-Chief: Noel R. Rose, M.D., Ph.D.

Publisher: Peter H. Rheinstein, M.D., J.D., M.S.

Executive Editor: Benjamin Yang, M.D., Ph.D.

Senior Editors: Jacques Banchereau, Ph.D.; David Borchelt, Ph.D.; Eugene Braunwald, M.D.; C. Garrison Fathman, M.D.; John D. Gearhart, Ph.D.; Donald L. Price, M.D.; Stanley B. Prusiner, M.D.; J. Craig Venter, Ph.D.; Bert Vogelstein, M.D.

Editors: Maria G. Castro, Ph.D.; Paul B. Fisher, M.Ph., Ph.D.; Hakon Hakonarson, M.D., Ph.D.; Simon S. Lo, M.D.; John D. Mountz, M.D., Ph.D.; Alan Spatz, M.D.; George C. Tsokos, M.D.; Anas Younes, M.D.

Associate Editors: Patrizio Caturegli, M.D.; David Eve, Ph.D.; Peter Gao, M.D.; Alan Y. Lu, Ph.D.; Philip Musk, Ph.D.; Max Oppenheimer, J.D., Esq.; James J. Wang, M.D., Ph.D.

Copy Editor: Karen Hudson


Editor-in-Chief

Noel R. Rose, M.D., Ph.D.

Dr. Rose is the Director of Center for Autoimmune Disease Research and a Professor in the Department of Pathology (with joint appointment in Department of Medicine), the Johns Hopkins University School of Medicine and a Professor in the W. Henry Feinstone Department of Molecular Microbiology and Immunology, the Johns Hopkins University Bloomberg School of Public Health. Dr. Rose also served as the Chairman of the Autoimmune Diseases Coordinating Committee of the National Institutes of Health and a principal advisor to the then U.S. NIH Director Dr. Elias A. Zerhouni. He has been the Chairman of the W. Henry Feinstone Department of Molecular Microbiology and Immunology of the Johns Hopkins University Bloomberg School of Public Health for more than a decade.

Dr. Rose’s pioneering studies on autoimmune thyroiditis and myocarditis helped to initiate the modern era of research on autoimmune diseases. Dr. Rose and his colleagues have continued to contribute to our understanding of autoimmunity, including the first demonstration of the genetic factors responsible for predisposition to autoimmune disease and more recent investigations on the roles of infection and environmental agents in the initiation of autoimmune disease in genetically predisposed individuals.

Dr. Rose is the co-author of the textbook The Autoimmune Diseases (now 3rd edition) and former Editor-in-Chief of Clinical Immunology. He is currently the Editor-in-Chief of The Year in Immunology.


Publisher

Peter H. Rheinstein, M.D., J.D., M.S.

Dr. Rheinstein holds an M.D. from the Johns Hopkins University School of Medicine and a J.D. from the University of Maryland, Baltimore. He is board certified in family practice and holds a certificate of added qualifications in geriatrics. Dr. Rheinstein has studied at both Harvard University and the Brookings Institution.

Dr. Rheinstein is the president of Academy of Pharmaceutical Physicians and Investigators (APPI) and is a past president of the Drug Information Association (DIA). He also served on the Board of Trustees of the American Academy of Pharmaceutical Physicians. He had a distinguished career at the U.S. Food and Drug Administration, having held senior management positions, lastly as the Director of Medical Staff, The Office of the Commissioner of the U.S. FDA.

Dr. Rheinstein was the senior vice president for medical and clinical affairs at Cell Works, a Johns Hopkins technology spin-off firm developing cancer diagnostics and therapeutics, and the medical director for a national chain of extended care facilities. He has served APPI as its vice president for American Medical Association (AMA) Relations and delegate to the AMA House of Delegates, vice chair of the Policy Committee and Government Affairs Committee, and president of the Baltimore-Washington Chapter. He received the APPI President’s Outstanding Service Award in 2003.


Executive Editor

Benjamin Yang, M.D., Ph.D.

After completing his medical school education, Dr. Yang received a Ph.D. in Immunology and Molecular Microbiology from the Johns Hopkins University in 1996. Dr. Yang continued his research on autoimmune diseases at Johns Hopkins first as an NIH Fellowship Award recipient and then as a faculty member.

For more than 10 years at Johns Hopkins, Dr. Yang investigated the mechanisms of autoimmune diseases at the genetic, cellular, functional, and disease levels. Dr. Yang investigated the tri-molecular relationship between MHC (major histocompatibility complex), antigen, and T cell receptor at the DNA and protein levels and how this pivotal relationship would predict the occurrence of autoimmune diseases. To accomplish the tasks, he produced tens of thousands of T cell hybridoma clones with unprecedented accuracy and efficiency, and sequenced the T cell receptor genes in a significant portion of these clones. In collaboration with scientists at the NIH using a set of the genes he discovered, Dr. Yang and his colleagues successfully created a transgenic mouse strain which has become a model for investigating autoimmune diseases.

Dr. Yang was a Senior Research Scientist and Head of the Immunology Group at Cell Works, a Johns Hopkins technology spin-off, responsible for isolating and testing compounds that boost immune responses to cancer cells. He was the first Director of Research and established and expanded the Research Department at PCI, evaluating current and experimental therapies.


Senior Editors

Jacques Banchereau, Ph.D.

Dr. Banchereau is the Max and Gayle Clampitt Chair for Immunology Research, the W. W. Caruth, Jr. Chair in Transplant Immunology, and the Director of the Baylor Institute for Immunology Research at Baylor Research Institute, Dallas.

Dr. Banchereau served as Director of the Schering Plough Laboratory for Immunological Research near Lyon, France, where he was among the first to discover how to grow human dendritic cells, a type of immune cells. Dr. Banchereau has been an inventor/co-inventor of 16 patents and patent applications in the field of biotechnology.

Dr. Banchereau joined Baylor in 1996 to develop the Institute for Immunology. He also served on the National Institutes of Health’s Experimental Immunology Study Section, Center for Scientific Review, in the area of experimental immunology. He has published more than 275 papers and 170 book chapters and reviews in major international journals. He speaks frequently at national and international scientific conferences. His research interests center around various areas of immunology (including transplantation immunology) and cancer including dendritic cells, novel cytokines, and antibody-producing B lymphocytes. Dr. Banchereau is considered the “father” of dendritic cell research. Using dendritic cell technology, Dr. Banchereau is seeking ways to manipulate the immune system to prevent rejection of transplanted organs and induce tolerance and potentially provide cures for a range of diseases, including cancer, autoimmune diseases such as lupus, rheumatoid arthritis, and type 1 diabetes, and infectious diseases such as AIDS.

David Borchelt, Ph.D.

Dr. Borchelt is a Professor of Neuroscience and the Director of Santa Fe Health Alzheimer’s Disease Research Center of University of Florida College of Medicine. He is also an Investigator of the McKnight Brain Institute of University of Florida. Before joining University of Florida, he was an Associate Professor of Pathology in the Johns Hopkins University School of Medicine.

A number of neurodegenerative disorders including familial Alzheimer’s disease, familial amyotrophic lateral sclerosis, and Huntington’s disease are progressive and fatal and result from the dysfunction and death of specific populations of nerve cells. In all of these disorders, a change in the amino acid sequence of specific proteins initiates a cascade of events that lead to disease. A common feature of these disorders is the accumulation of misfolded proteins or peptides in regions of the CNS affected by each disease.

Dr. Borchelt’s laboratory investigates the molecular processes by which specific mutant proteins cause disease. His work involves the use of transgenic mouse models, knockout mice, and cell culture systems to examine the effect of mutations on the function and biology of the mutated proteins. Collectively, these approaches provide insights into the molecular mechanisms of disease and have the potential to identify new therapeutic strategies for these disorders.

Eugene Braunwald, M.D.

At Harvard Medical School, Dr. Braunwald is the Distinguished Hersey Professor of Medicine and The Theory and Practice of Physic. Established in 1783, it is one of the earliest endowed professorships in Harvard and the United States. Dr. Braunwald is the Faculty Dean for Academic Programs in the Partners HealthCare System, founded by the Brigham and Women’s Hospital and Massachusetts General Hospital.

Dr. Braunwald graduated first in his class of doctoral degree recipients at New York University, where he also earned his A.B., and completed his residency at the Johns Hopkins Hospital. He served as chief of cardiology and clinical director at the National Heart, Lung and Blood Institute; founded the Department of Medicine at the University of California, San Diego; and from 1972 to 1996 chaired the Department of Medicine at Brigham and Women’s Hospital.

The only cardiologist who is a member of the National Academy of Sciences, Dr. Braunwald has received a number of awards and honors. In 1996, Harvard created the Eugene Braunwald Professorship in Medicine as a permanently endowed chair, and in 1999 the American Heart Association established the annual Eugene Braunwald Academic Mentorship Award. Dr. Braunwald has written more than 1,100 publications, been Editor-in-Chief of the leading textbook Harrison’s Principles of Internal Medicine, and is the founding editor of Heart Disease, the leading cardiology text.

C. Garrison Fathman, M.D.

Dr. Fathman is a Professor of Medicine and Chief of the Division of Immunology and Rheumatology at Stanford University School of Medicine. He serves as Past Chairman of the Federation of Clinical Immunology Societies (FOCIS) and Director of the Center for Clinical Immunology at Stanford (CCIS).

Dr. Fathman’s contributions in translational medicine in the areas of cellular and molecular immunology have brought him international recognition. In particular, he is acclaimed for his establishment and exploitation of the technologies of antigen-specific T-cell cloning and adoptive cellular gene therapy, accomplishments that have facilitated a remarkable series of subsequent advances in understanding conventional immune response and treating autoimmune diseases.

As the Director of the CCIS, the Stanford-based FOCIS Center of Excellence, Dr. Fathman has initiated multi-disciplinary studies to generate novel approaches for the treatment of autoimmune diseases, including insulin-dependent diabetes mellitus, rheumatoid arthritis, and multiple sclerosis. He has also developed state-of-the-art technologies of genomics, proteomics, and metabolomics to integrate approaches to diagnosis, prognosis, and therapy of these diseases.

Dr. Fathman is the past President of the Clinical Immunology Society. He was an Associate Editor of the prestigious Annual Review of Immunology for 25 years and serves on the editorial boards of a number of scientific journals.

John D. Gearhart, Ph.D.

Dr. Gearhart is a Penn Integrates Knowledge Professor, the James W. Effron University Professor, and the Director of the Institute for Regenerative Medicine at the University of Pennsylvania (since 2008). Prior to joining University of Pennsylvania, he was the C. Michael Armstrong Professor of Medicine and Director of the Stem Cell Program of the Institute for Cell Engineering at the Johns Hopkins University School of Medicine. He was also a professor of gynecology and obstetrics, physiology, and comparative medicine in the Johns Hopkins University School of Medicine and professor of biochemistry and molecular biology in the Johns Hopkins University Bloomberg School of Public Health.

Dr. Gearhart is a developmental geneticist and his research has been directed at the understanding of the molecular and cellular basis of human embryonic development. Dr. Gearhart is a leader in the development and use of human reproductive technologies and in the genetic engineering of cells. Dr. Gearhart is a pioneer in stem cell research. In 1998, Dr. Gearhart and his research team at Johns Hopkins published the first report on the derivation of pluripotent stem cells from germ cells of the human embryo. His research focuses on the basic science of stem cells, stem cell specialization, and the generation of cell-based therapies for a number of diseases and injuries.

Dr. Gearhart is a founding member of the International Society for Stem Cell Research and serves on a number of advisory boards and committees of foundations, institutes, and professional societies involved in stem cell research and policy. He also served as a consultant or expert witness for a number of governmental agencies at the national and international levels.

Donald L. Price, M.D.

Dr. Price is a Professor of Pathology, Neurology, and Neuroscience at the Johns Hopkins University School of Medicine and is the Director of Johns Hopkins Alzheimer’s Disease Research Center. He is a clinical neurologist-neuropathologist-neurobiologist, who has made major contributions to the understanding of a variety of human neurodegenerative diseases, particularly Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. He has a distinguished collection of publications in several fields, including the study of aforementioned neurodegenerative diseases, the development and analysis of animal models - especially genetically engineered models of these disorders, and the investigation of experimental therapeutic strategies that translate basic science discoveries to treatments of human neurological illnesses. The Johns Hopkins University has established The Donald L. Price Research Fund in honor of Dr. Price’s major contributions.

Dr. Price is the author of more than 500 publications in scientific journals. He has been recognized by the international scientific and medical communities, as illustrated by his ranking among the top ten neuroscientists who authored high impact papers in neuroscience according to Science Watch (2001).

Dr. Price has received numerous honors and awards, including two Javits Neuroscience Investigator Merit Awards from the National Institute of Neurological Disorders and Stroke, a Leadership in Alzheimer’s Disease Award from the National Institute on Aging, and the Potamkin Prize for Alzheimer’s Disease Research and Wartenberg Award from the American Academy of Neurology. He was President of the Society for Neuroscience (2000-2001), and is a member of The Institute of Medicine (National Academy of Sciences).

Stanley B. Prusiner, M.D.

Dr. Prusiner is the Director of the Institute for Neurodegenerative Diseases and a Professor of Neurology and Biochemistry at the University of California, San Francisco (UCSF) where he has worked since 1972. He received his undergraduate and medical training at the University of Pennsylvania, Philadelphia and his postgraduate clinical training at UCSF. From 1969-72, he served in the U.S. Public Health Service at the National Institutes of Health. Dr. Prusiner is the editor of 12 books and the author of over 350 research articles, and his contributions to scientific research are internationally recognized.

Dr. Prusiner is the discoverer of prion, the pathologic agent of mad cow disease and Creutzfeldt-Jakob disease. Dr. Prusiner won the Nobel Prize in Physiology or Medicine in 1997 and is the recipient of the (U.S.) National Medal of Science in 2010.

Dr. Prusiner is a member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences, the American Philosophical Society, and a foreign member of the Royal Society, London. Besides the Nobel Prize and National Medal of Science, Dr. Prusiner is the recipient of a number of other prestigious prizes, including the Potamkin Prize for Alzheimer’s Disease Research from the American Academy of Neurology (1991), the Richard Lounsberry Award for Extraordinary Scientific Research in Biology and Medicine from the National Academy of Sciences (1993), the Gairdner Foundation International Award (1993), the Albert Lasker Award for Basic Medical Research (1994), the Paul Ehrlich Prize from the Federal Republic of Germany (1995), the Wolf Prize in Medicine from the State of Israel (1996), the Keio International Award for Medical Science (1996), and the Louisa Gross Horwitz Prize from Columbia University (1997).

J. Craig Venter, Ph.D.

Dr. Venter is regarded as one of the leading scientists of the 21st century for his numerous invaluable contributions to genomic research. He is Founder and President of the J. Craig Venter Institute (JCVI), a not-for-profit research organization with more than 400 scientists and staff members, focusing research on human, microbial, plant, environmental, and synthetic genomics, and seeking alternative energy solutions through genomics.

Dr. Venter developed Expressed Sequence Tags or ESTs, a revolutionary new strategy for rapid gene discovery. In 1992, Dr. Venter founded The Institute for Genomic Research (TIGR), a not-for-profit research institute, where in 1995 he and his team for the first time decoded the genome of a free-living organism, the bacterium Haemophilus influenza, using his new whole genome shotgun technique. Dr. Venter and his teams have since sequenced hundreds of genomes.

In 1998, Dr. Venter founded Celera Genomics to sequence the human genome. The successful completion of this monumental project culminated with the February 2001 publication of the human genome in the journal Science. He and his team at Celera Genomics also sequenced the fruit fly, mouse, and rat genomes.

Dr. Venter is one of the most frequently cited scientists and is the author of more than 200 research articles. He is also the recipient of a number of honors and awards, including the Paul Ehrlich and Ludwig Darmstaedter Prize (2001) and the Gairdner Foundation International Award (2002). Dr. Venter is a member of a number of prestigious scientific organizations including the National Academy of Sciences, the American Academy of Arts and Sciences, and the American Society for Microbiology.

Bert Vogelstein, M.D.

Dr. Vogelstein is the Clayton Professor of Oncology and Pathology and the Director of the Ludwig Center for Cancer Genetics and Therapeutics at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine. He has been an Investigator at the Howard Hughes Medical Institute since 1995.

Dr. Vogelstein is the number one most cited scientist over a 20-year period from 1983 to 2002 among all categories/branches of science, according to Science Watch (2003). During this period, Dr. Vogelstein’s 361 published papers were cited 106,401 times by other scientists. In a series of illuminating studies published from 1985 to 1993, Dr. Vogelstein and his colleagues described the genetic mechanisms of colon cell cancer transformation that progresses in successive stages over 20-30 years. The discovery set forth a new era in the understanding of the making of a cancer.

Dr. Vogelstein is a member of the U.S. National Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences, the American Philosophical Society, and the European Molecular Biology Organization.

Dr. Vogelstein received numerous prestigious awards, including Richard Lounsbery Award from National Academy of Sciences, Gairdner Foundation International Award in Science, Paul Ehrlich and Ludwig Darmstaedter Prize from Paul Ehrlich Foundation, and William Allan Award from American Society of Human Genetics.


Editors

Maria G. Castro, Ph.D.

Dr. Castro is Professor of Neurosurgery and Professor of Cell and Developmental Biology at the University of Michigan Medical School, Ann Arbor, Michigan.

From 2001 to 2011, Dr. Castro was Professor of Medicine and Professor of Biomedical Sciences and Co-Director of the Board of Governors Gene Therapeutics Research Institute at Cedars-Sinai Medical Center. She was also Professor of Medicine and Professor of Molecular and Medical Pharmacology at the David Geffen School of Medicine, University of California Los Angeles. Dr. Castro received the “Medallions’ Group Endowed Chair in Cancer Gene Therapeutics.” She serves as a permanent member of the NST-1 Study Section, National Institute of Neurological Disorders and Stroke, NIH. She has published over 200 articles, reviews, and book chapters and serves as a mentor and role model to many young scientists, Ph.D. students, and interns. She also serves on numerous Journals’ Editorial Boards.

Dr. Castro’s research focuses on understanding the mechanisms that elicit the regression of cancer mediated by the immune system, the role of the microenvironment in mediating tumor progression, and the inhibition of angiogenesis with the goal of developing new treatments aimed at eradicating brain cancer.

Paul B. Fisher, M.Ph., Ph.D.

Dr. Fisher is Professor and Chairman of the Department of Human and Molecular Genetics and Director of the VCU Institute of Molecular Medicine, and he holds the Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond, Virginia.

Dr. Fisher’s research focuses on three broad areas: cancer, neurodegeneration, and infectious diseases. He is interested in defining the fundamental mechanisms underlying disease development and pathogenesis with a primary objective to move discoveries made in the laboratory into the clinic, the concept of “bench-to-bedside.” His laboratory pioneered the use of subtraction hybridization for genomic discovery and developed novel approaches for enhancing cancer therapy (small molecule inhibitors, cancer terminator viruses), imaging (PEG-Prom based imaging approaches), and theranostics (combining imaging and therapy in a single application).

Dr. Fisher is among the top 5% of NIH funded investigators over the past 25 years, has published over 400 original research papers and review articles, and serves on many US government and private review panels. Dr. Fisher has 55 issued US and international patents and was founder of the functional genomics company GenQuest Inc., which merged with Corixa Corporation, a publicly traded biopharmaceutical company subsequently acquired by GlaxoSmithKline.

Hakon Hakonarson, M.D., Ph.D.

Dr. Hakonarson is an Associate Professor of Pediatrics at The University of Pennsylvania School of Medicine. He is a physician-scientist and director of The Children’s Hospital of Philadelphia (CHOP)’s Center for Applied Genomics (CAG), a high-throughput highly automated genotyping facility founded to identify the genetic causes of complex medical disorders in children, such as autism and cancer, with the objective of developing new therapies. The Center represents a $40 million commitment from CHOP to genotype approximately 100,000 children, a research undertaking that has gained nationwide attention, including news features in the Wall Street Journal, New York Times, Time magazine, Nature, and Science.

Dr. Hakonarson has served previously in several senior posts in the biopharmaceutical industry, including vice president of Clinical Sciences and Development and Chief Scientific Officer. Dr. Hakonarson has also been the principal and co-principal investigator on several NIH-sponsored grants, and he has published numerous high-impact papers on genomic discoveries and their translations. Time magazine listed Dr. Hakonarson’s autism gene discovery reported in Nature in 2009 among the top 10 medical breakthroughs of that year.

Simon S. Lo, M.D.

Dr. Lo has served on the faculty at the Indiana University Cancer Center and Arthur G. James Cancer Hospital, Ohio State University. He is currently the Director of Neurologic Radiation Oncology and Gamma Knife Radiosurgery and Associate Professor at University Hospitals Seidman Cancer Center, Case Western Reserve University.

Dr. Lo’s research interest is in delivering stereotactic radiation to all body sites. He is the Vice-Chair of the American College of Radiology Appropriateness Criteria Bone Metastasis Expert Panel and Member of the American Society for Radiation Oncology Bone and Brain Metastasis Taskforce. His collaborative work on radiobiologic modeling for ablative radiation dose range with his colleagues at Ohio State University has been recognized internationally. He has more than 65 peer-reviewed publications and over 20 book chapters and has lectured in national and international meetings. He is editing a textbook on stereotactic body radiation therapy together with other experts in the field.

John D. Mountz, M.D., Ph.D.

Dr. Mountz is currently Professor of Medicine at the University of Alabama at Birmingham (UAB). Dr. Mountz is the recipient of the J. W. & Virginia Goodwin-Warren D. Blackburn, Jr. Research Chair in Rheumatology (2002) and the Max Cooper Award for Excellence in Research (2003). Dr. Mountz received the UAB Dean’s Award for Excellence in Mentorship in 2008 for his dedication in research training. Dr. Mountz has published greater than 200 papers on the topic of autoimmunity and aging.

Dr. Mountz’s research focuses on autoimmune mechanisms mediated by IL-17 on B cells. Dr. Mountz has analyzed a novel BXD2 mouse model that spontaneously develops germinal centers, high titers of autoantibodies, and a chronic erosive arthritis. Dr. Mountz also analyzes human rheumatoid arthritis synovial fibroblasts (RASF). More recently, Dr. Mountz and colleagues have developed a new strategy to isolate mononuclear cells and synovial fibroblasts from synovial fluid of patients with rheumatoid arthritis and osteoarthritis.

Alan Spatz, M.D.

Dr. Spatz is Director of the Department of Pathology at the Jewish General Hospital, and Professor of Pathology and Oncology at McGill University. Dr. Spatz is also Program Director of the McGill Integrated Cancer Research Training Program. He holds a Canada Research Chair in Molecular Pathology.

Dr. Spatz is Chairman of the National Cancer Institute of Canada Melanoma Committee. Dr. Spatz served as Chairman of the Melanoma Group of the European Organization for Research and Treatment of Cancer, and as President of the French Division of the International Academy of Pathology. He currently serves as a board member of several international professional organizations and on editorial boards and international strategic committees.

Dr. Spatz leads an international research group on cutaneous melanoma. His current research involves the X chromosome role in metastatic potential and key factors associated with cancer progression. He has authored more than 170 original scientific papers, reports, review articles, and books.

George C. Tsokos, M.D.

Dr. Tsokos is Professor of Medicine, Harvard Medical School and Chief, Rheumatology Division, Beth Israel Deaconess Medical Center in Boston, Massachusetts.

Dr. Tsokos is past President of the Clinical Immunology Society and has held leadership positions with the American College of Rheumatology. He has served as Chair of the Committee on Hypersensitivity, Autoimmunity and Immune Mediated Diseases of NIH. He is the current Editor-in-Chief of Clinical Immunology and has served as editor of several journals. Dr. Tsokos has been elected to the Association of American Physicians, Fellow of the American Association for the Advancement of Sciences, and Master of the American College of Physicians.

Dr. Tsokos’s research focuses on the cellular and molecular pathogenesis of systemic lupus erythematosus. His laboratory has opened and led the field of molecular abnormalities on immune cells in patients with lupus and has introduced novel treatment targets and biomarkers.

Anas Younes, M.D.

Anas Younes, M.D., is Professor of Medicine, University of Texas M. D. Anderson Cancer Center and Director of Clinical and Translational Research at the Department of Lymphoma and Myeloma at M.D. Anderson.

Dr. Younes is a member of the National Cancer Institute Lymphoma Steering Committee and serves on several scientific journal editorial boards and NIH Study Sections. His laboratory is supported by a P50 SPORE grant on lymphoma. Dr. Younes’s clinical and translational research is focused on the development of novel targeted therapy for patients with Hodgkin’s lymphoma and non-Hodgkin’s lymphoma.


Associate Editors

Patrizio Caturegli, M.D.
Associate Professor of Pathology, Johns Hopkins University School of Medicine and Associate Professor of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

David Eve, Ph.D.
Instructor, Center for Aging Neuroscience, University of South Florida, Tampa, Florida; Associate Editor, Cell Transplantation, Tampa, Florida

Peter Gao, M.D.
Program Director, Division of Metabolism and Health Effects, National Institute on Alcohol Abuse and Alcoholism, NIH, Rockville, Maryland

Alan Y. Lu, Ph.D.
Executive Vice President for Product Development, Sirnaomics, Inc., Gaithersburg, Maryland

Philip Musk, Ph.D.
Senior Staff Scientist, Gene Logic Inc., Gaithersburg, Maryland

Max Oppenheimer, J.D., Esq.
Associate Professor of Law (Patent, Copyright, and Trademark Law; Pharmaceutical Law), Johns Hopkins University and University of Baltimore, Baltimore, Maryland

James J. Wang, M.D., Ph.D.
Neurologist (Vascular Neurology), Wesley Neurology Clinic, Memphis, Tennessee


Editorial and Content Manager

Karen Hudson
Discovery Medicine, Baltimore, Maryland

 
Close
  • E-mail
E-mail It